Gnanendran, Subashini SMiller, JamesArcher, ChristineJain, SwaranjaliHwang, Shelley J EPeters, GeoffreyMiller, Andrew2023-08-090960-8931http://hdl.handle.net/1885/295468Immune checkpoint inhibitors have become the mainstay of treatment for metastatic melanoma. This article presents a new case of acquired generalised lipodystrophy (AGL) during anti-programmed cell death-1 (anti-PD-1) therapy and a systematic review of the literature with an aim to further understand the pathogenesis. A comprehensive search was conducted using PubMed, Embase, MEDLINE and Cochrane Central databases. We identified four cases of lipodystrophy associated with anti-PD-1 immunotherapy, including our own. Of these, three were associated with nivolumab, and one with pembrolizumab. Body composition changes occurred at a median of 7 months after anti-PD-1 initiation. All cases reported AGL, with subcutaneous fat loss affecting majority of the body. There were three reported cases of insulin resistance associated with AGL. AGL should be a recognised adverse event associated with anti-PD-1 therapy.application/pdfen-AU© 2020 The authorsanti-programmed cell death-1cutaneous adverse eventsgeneralised lipodystrophyimmune checkpoint inhibitorimmunotherapylipodystrophy202010.1097/CMR.00000000000006602022-07-24